is generally classified based on its primary intended use between its medicinal and device components. The distinction is essential because it determines the applicable regulations each component must adhere to under EU MDR.

Organizations seeking to develop and market combination products must first determine how their products align with the definitions set out in Article 117. This understanding will set the stage for compiling necessary documentation and supporting data through the various phases of regulatory approval. Additionally, definitions provided in the General Safety and Performance Requirements (GSPR) and Annex II of the EU MDR will further clarify expectations for product safety and efficacy.

Documenting clear correlations between device and medicinal product functions, along with their intended uses, will be fundamental in subsequent stages of the regulatory pathway. A comprehensive leveraging of the guidelines as outlined by the European Commission and consultation with Notified Bodies can provide additional support in aligning product specifics with regulatory requirements.

Step 2: Preparing the Technical Documentation

The next phase in complying with Article 117 involves the meticulous preparation of the technical documentation required under the EU MDR. This documentation serves as an essential part of the submission to Notified Bodies for evaluation before market access.

Key elements of the technical documentation include:

• Product Description: Provide an exhaustive description of the combination product, explaining how device and medicinal components work together.
• Intended Use and Indications for Use: Clearly define the intended purpose of both the medical device and the medicinal product. This should include the clinical implications and user instructions.
• Compliance with GSPR: Address how the product meets the General Safety and Performance Requirements outlined in Annex I of the regulation.
• Clinical Data: Submit robust clinical data that reflects safety and efficacy, particularly if the product is not covered by existing clinical assessments. This may involve clinical trials and/or relevant literature reviews.
• Risk Management: Following ISO 14971 guidelines, document your risk management approach, including risk assessment and mitigation strategies for both components.
• Manufacturing Information: Provide insights into the manufacturing processes, quality control measures, and any changes involved in the integration of the medicinal and device components.

Furthermore, organizations must ensure that their technical documentation is complete, coherent, and consistent, providing easy navigation for regulatory reviewers. Engaging EU MDR consulting services at this juncture can enhance the quality and completeness of the submission, increasing the likelihood of regulatory success.

Step 3: Engaging a Notified Body

Following the preparation of the technical documentation, engaging a Notified Body is a critical step in the Article 117 pathway. Notified Bodies are independent organizations designated by EU member states to assess whether products meet EU regulations before they can be placed on the market.

Selecting a Notified Body involves several considerations:

• Scope of Designation: Ensure that the Notified Body you approach is designated for the specific product types and classifications relevant to your combination product.
• Expertise in Combination Products: Preferably select a Notified Body that has a proven track record in dealing with combination products and the associated complexities.
• Historical Performance: Assess the responsiveness and historical timeline of the selected Notified Body in handling submissions; this can influence your time to market.

Once a suitable Notified Body has been selected, the next step is to submit the technical documentation accompanied by a detailed application for assessment. It is critical to maintain open communication and provide timely responses to any queries or requests for further information from the Notified Body throughout the evaluation process.

During this evaluation phase, expect reviews of clinical data, manufacturing processes, and compliance with the GSPR. Strong documentation, aligned with regulatory expectations, enhances the assessment process and contributes positively to the decision-making outcome.

Step 4: Addressing Clinical Evaluation Requirements

Article 117 imposes specific obligations regarding clinical evaluation as part of the conformity assessment for combination products. It mandates that manufacturers must provide sufficient and robust clinical evidence supporting the safety and efficacy of the combination product.

The process of clinical evaluation for a combination product involves several essential steps:

• Literature Review: Conduct a thorough review of existing literature that is relevant to the medicinal product and the device. This review must demonstrate its correlation with the intended use and population.
• Clinical Trials: If the literature review does not provide adequate evidence of safety and efficacy, you may need to perform clinical trials. This step must follow ICH-GCP guidelines and the specific provisions of the EU MDR concerning clinical investigations.
• Evidence Compilation: Aggregate all evidence from literature and trials that validate the clinical claims of your combination product. The evidence gathered will support the clinical evaluation report required for submission.

It’s important to collaborate closely with clinical evaluators and regulatory experts to ensure that the collected data not only meets regulatory standards but is also presented cohesively in the final documentation package.

Step 5: Submission of Application and Technical Documentation

Once the documentation is complete and the engagement with the Notified Body established, the next critical phase is the submission of the application alongside comprehensive technical documentation. This submission is directed at obtaining CE marking, allowing the product to enter the European market.

When assembling the submission package, consider the following:

• Cover Letter: Prepare an executive cover letter summarizing the purpose and the nature of the submission, stating critical aspects like product classification.
• Technical Documentation:** Include the completed technical file demonstrating adherence to the EU MDR regulations, including any amendments that might be relevant.
• Evidence of Conformity Assessment: Append the evidence proving compliance to the applicable requirements, including test reports, risk assessments, and any relevant historical data.
• Fees and Payment Information: Include information regarding submission fees as outlined by the selected Notified Body.

Following submission, monitor the progress of application review rigorously. This phase might involve multiple rounds of communication and clarifications with the Notified Body. Act promptly on any feedback received and document all exchanges meticulously to maintain traceability.

Step 6: Responding to Notified Body Queries and Review Process

Throughout the review process, it is common for Notified Bodies to issue queries regarding the submitted technical documentation. It is crucial to manage this feedback proactively to move towards successful compliance.

Key actions include:

• Prepare Responses: Establish a structured process for preparing responses to queries. Each response must be specific, concise, and directly address the points raised by the Notified Body.
• Maintain Documentation: Keep thorough records of questions, responses, and pertinent communications. This documentation will serve as a reference for future audits and regulatory engagements.
• Continuous Engagement: Stay in regular contact with your Notified Body throughout this phase, showing commitment to resolving any outstanding issues efficiently.

A swift and collaborative approach can facilitate a smoother review process, hastening eventual market access for the combination product. Reassessing the technical documentation for clarity and coherence before resubmission could also reduce the chance of additional queries.

Step 7: Market Access and Post-Market Surveillance Obligations

Upon successful review and recommendation from the Notified Body, the combination product will receive a CE mark, granting access to the European market. However, compliance does not end with market approval; ongoing obligations must be fulfilled under the regulations.

Post-market surveillance and vigilance are mandatory for tracking the product’s safety and performance once on the market. Manufacturers are required to:

• Monitor Product Performance: Develop mechanisms for collecting feedback from clinical users and patients regarding the performance of the combination product.
• Reporting Adverse Events: Establish systems for reporting any adverse events or product issues to the authorities through the European Database on Medical Devices, or EUDAMED.
• Regular Studies and Reviews: Conduct periodic reviews of clinical data to assess ongoing compliance and risk and make adjustments based on new scientific evidence or reports.

Additionally, the continuous engagement with healthcare professionals and stakeholders can provide invaluable insight into product usage and potential improvements, further ensuring compliance and fostering reputation in the market. Active participation in post-marketing surveillance can address regulatory demands and contributes to patient safety and product reliability.

Step 8: Preparing for Audits and Inspections

External audits and inspections may occur to verify ongoing compliance with EU MDR and the requirements of Article 117. Preparing for these audits is essential to ensure organizational readiness and full compliance.

To effectively manage the inspection process, organizations should:

• Review Internal Processes: Conduct internal audits of compliance across departments, ensuring that all documentation and processes meet regulatory requirements.
• Staff Training: Ensure that staff members involved in regulatory compliance are well-trained and informed about current regulations and audit processes.
• Documentation Accessibility: Maintain organized and accessible documentation to facilitate the audit process. Preparedness conveys diligence and commitment to quality.

Underscoring a culture of compliance and continual improvement within the organization will not only prepare teams for audits but also enhance overall product quality and reliability in the long run.

In conclusion, understanding and implementing Article 117 within the context of EU MDR for combination products requires meticulous planning and execution across various phases. Following a structured approach—from understanding regulatory classifications to ongoing compliance monitoring—ensures that products meet necessary safety and efficacy standards while fostering successful market entry and sustained performance.